$NOVO B #Novo Nordisk A/S B Novo Nordisk - Sema 2.4mg is an obesity game-changer: Semaglutide obesity ph3 programme now concluded As expected, also strong STEP 2 and STEP 3 trial results Ph3 results bodes well for LT obesity odyssey.… https://t.co/L4nKqVXWop #equity #stocks https://t.co/4pniWcCY9M